RxDoctor Payments Data

Saiyed Ali, MD

Internal Medicine · Sacramento, CANPI 1639607294

Payments from drug & device makers

$781in general payments, 2019–2025

Across 25 payments — averaging $31.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$240
  • AstraZeneca$223
  • Bayer$130
  • Abbott$90
  • Boehringer Ingelheim$61
  • Vifor Pharma, Inc.$19
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$75597%
  • Education$253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$781 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$191,794
Medicare patients
327
Services billed
1,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tolvaptan11$94,330
FarxigaDapagliflozin Propanediol40$30,485
VeltassaPatiromer Calcium Sorbitex30$23,416
Sevelamer Carbonate40$19,328
KerendiaFinerenone16$14,669
LokelmaSodium Zirconium Cyclosilicate11$12,470
Calcium Acetate16$1,970
Tamsulosin Hcl74$1,058
Nifedipine ErNifedipine40$768
Losartan Potassium65$711
Amlodipine Besylate163$437
Tacrolimus12$370
Furosemide74$271
Hydralazine Hcl30$269
Lisinopril41$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$223$42,95551 claims
BayerKerendia$130$14,66916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →